Adverse effects from immunotherapy treatment in melanoma patients are associated with a distinct pattern of
gene expression, offering the possibility for improved therapeutic strategies.
Health Professionals
Beyond the slip and slop for keratinocyte skin cancer
For patients with a high burden of non-melanoma cancers, there is more to prevention than just sun avoidance and regular checks and excisions.
Adjuvant Pembrolizumab Does Not Affect Long-Term HRQOL in Stage III Melanoma
Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.
First-Line Nivolumab/Relatlimab vs Nivolumab/Ipilimumab in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the two regimens: RELATIVITY-047 and CheckMate 067, respectively. No direct comparisons of the regimens in this setting have been reported previously.